# Precision Optics Corporation, Inc.: overview POCI · Nasdaq · CIK 867840 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/poci.md) · [Financials](/companies/poci/financials.md) · [Filings](/companies/poci/filings.md) · [Insiders](/companies/poci/insiders.md) Latest reported revenue: [$8.8m](/filings/0001683168-26-007462.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 28, 2026 (XBRL us-gaap:Revenues, accession 0001683168-26-007462). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [4,197](/filings/0001683168-25-008330.md) | [4,527](/filings/0001683168-26-001109.md) | [4,186](/filings/0001683168-26-003818.md) | [6,181 d](/filings/0001683168-26-007462.md) | [6,681](/filings/0001683168-25-008330.md) | [7,368](/filings/0001683168-26-001109.md) | [8,709](/filings/0001683168-26-003818.md) | [8,774 d](/filings/0001683168-26-007462.md) | | Gross margin | % | [26.6%](/filings/0001683168-25-008330.md) | [23.6%](/filings/0001683168-26-001109.md) | [10.0%](/filings/0001683168-26-003818.md) | [12.9% d](/filings/0001683168-26-007462.md) | [14.2%](/filings/0001683168-25-008330.md) | [2.8%](/filings/0001683168-26-001109.md) | [23.6%](/filings/0001683168-26-003818.md) | [25.3% d](/filings/0001683168-26-007462.md) | | Operating margin | % | [(29.7%)](/filings/0001683168-25-008330.md) | [(20.1%)](/filings/0001683168-26-001109.md) | [(48.7%)](/filings/0001683168-26-003818.md) | [(21.9%) d](/filings/0001683168-26-007462.md) | [(23.9%)](/filings/0001683168-25-008330.md) | [(23.6%)](/filings/0001683168-26-001109.md) | [(0.7%)](/filings/0001683168-26-003818.md) | [(1.2%) d](/filings/0001683168-26-007462.md) | | Net margin | % | [(31.2%)](/filings/0001683168-26-003818.md) | [(21.4%)](/filings/0001683168-26-003818.md) | [(50.1%)](/filings/0001683168-26-003818.md) | [(22.7%) d](/filings/0001683168-26-007462.md) | [(24.5%)](/filings/0001683168-26-003818.md) | [(24.2%)](/filings/0001683168-26-003818.md) | [(1.2%)](/filings/0001683168-26-003818.md) | [(1.2%) d](/filings/0001683168-26-007462.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0001683168-25-008330.md) | [(0.15)](/filings/0001683168-26-001109.md) | [(0.30)](/filings/0001683168-26-003818.md) | not reported | [(0.21)](/filings/0001683168-25-008330.md) | [(0.23)](/filings/0001683168-26-001109.md) | [(0.01)](/filings/0001683168-26-003818.md) | not reported | | Free cash flow | $k | [(343)](/filings/0001683168-25-008330.md) | [(817) d](/filings/0001683168-26-001109.md) | [(2,000) d](/filings/0001683168-26-003818.md) | [(464) d](/filings/0001683168-26-007462.md) | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [15.7](/filings/0001683168-23-006801.md) | [21.0](/filings/0001683168-24-006760.md) | [19.1](/filings/0001683168-25-007305.md) | [19.1](/filings/0001683168-26-007462.md) | [31.5](/filings/0001683168-26-007462.md) | | Gross margin | % | [31.4%](/filings/0001683168-23-006801.md) | [36.8%](/filings/0001683168-24-006760.md) | [30.3%](/filings/0001683168-25-007305.md) | [17.8%](/filings/0001683168-26-007462.md) | [17.2%](/filings/0001683168-26-007462.md) | | Operating margin | % | [(9.7%)](/filings/0001683168-23-006801.md) | [(3.0%)](/filings/0001683168-24-006760.md) | [(14.3%)](/filings/0001683168-25-007305.md) | [(29.1%)](/filings/0001683168-26-007462.md) | [(11.1%)](/filings/0001683168-26-007462.md) | | Net margin | % | [(5.9%)](/filings/0001683168-23-006801.md) | [(0.7%)](/filings/0001683168-24-006760.md) | [(15.4%)](/filings/0001683168-25-007305.md) | [(30.3%)](/filings/0001683168-26-007462.md) | [(11.5%)](/filings/0001683168-26-007462.md) | | Diluted EPS | $ per share | [(0.18)](/filings/0001683168-23-006801.md) | [(0.03)](/filings/0001683168-24-006760.md) | [(0.49)](/filings/0001683168-25-007305.md) | [(0.85)](/filings/0001683168-26-007462.md) | [(0.43)](/filings/0001683168-26-007462.md) | | Free cash flow | $m | [(1.0)](/filings/0001683168-23-006801.md) | [(0.1)](/filings/0001683168-24-006760.md) | [(3.0)](/filings/0001683168-25-007305.md) | [(3.6)](/filings/0001683168-26-007462.md) | [(2.0)](/filings/0001683168-26-007462.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/poci/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEEDHAM INVESTMENT MANAGEMENT LLC](/funds/1167212.md) | 2026-06-30 | $8.5m | 1,670,550 | | Unchanged | | [MYDA Advisors LLC](/funds/1589689.md) | 2026-06-30 | $1.9m | 375,000 | | Reduced −25,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 325,751 | | Added +131,626 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $1.4m | 280,000 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $1.4m | 280,000 | | Unchanged | | [WealthTrust Axiom LLC](/funds/1425949.md) | 2026-06-30 | $1.3m | 260,458 | | Added +6,350 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $916.4k | 179,694 | | Added +35,900 | | [HighTower Advisors, LLC](/funds/1462245.md) | 2026-06-30 | $634.1k | 124,343 | | Added +27,778 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $337.4k | 66,137 | | Added +155 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $275.9k | 54,100 | | New +54,100 | ## Recent filings [All 510 filings](/companies/poci/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 16:17 ET | [8-K](/filings/0001683168-26-008197.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001683168-26-008197 | | 2026-10-27 | 16:15 ET | [DEF 14A](/filings/0001683168-26-008117.md) | Proxy statement, period 2026-12-10 | 0001683168-26-008117 | | 2026-09-28 | 16:30 ET | [8-K](/filings/0001683168-26-007465.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001683168-26-007465 | | 2026-09-28 | 16:15 ET | [10-K](/filings/0001683168-26-007462.md) | Annual report, period 2026-06-30 | 0001683168-26-007462 | | 2026-05-13 | 16:15 ET | [10-Q](/filings/0001683168-26-003818.md) | Quarterly report, period 2026-03-31 | 0001683168-26-003818 | | 2026-03-31 | 17:12 ET | [SCHEDULE 13D/A](/filings/0001140361-26-012384.md) | Ownership report, active investor, amended | 0001140361-26-012384 | | 2026-03-30 | 17:34 ET | [8-K](/filings/0001683168-26-002421.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001683168-26-002421 | | 2026-03-20 | 16:02 ET | [8-K](/filings/0001683168-26-002057.md) | 5.07 Shareholder vote results | 0001683168-26-002057 | | 2026-02-17 | 16:15 ET | [10-Q](/filings/0001683168-26-001109.md) | Quarterly report, period 2025-12-31 | 0001683168-26-001109 | | 2026-02-02 | 16:15 ET | [DEF 14A](/filings/0001683168-26-000669.md) | Proxy statement, period 2026-03-19 | 0001683168-26-000669 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001683168-26-007462.md), filed Sep 28, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/241c9563-e948-4a62-9bfe-f689c7a36b17) ## About the filer - CIK: 867840 - Tickers: POCI - Exchange: Nasdaq - SIC code: 3845 Electromedical & Electrotherapeutic Apparatus - State of incorporation: MA - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 16:26 ET. No prices; not investment advice.